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Background: Multipotent mesenchymal stromal cells (MSC) can be recovered from a variety of tissues in the body.
Yet, their functional properties were shown to vary depending on tissue origin. While MSC have emerged as a
favoured cell type for tendon regenerative therapies, very little is known about the influence of the MSC source on
their properties relevant to tendon regeneration.
The aim of this study was to assess and compare the expression of tendon extracellular matrix proteins and tendon
differentiation markers in MSC derived from different sources as well as in native tendon tissue. MSC isolated from
equine bone marrow, adipose tissue, umbilical cord tissue, umbilical cord blood and tendon tissue were
characterized and then subjected to mRNA analysis by real-time polymerase chain reaction.
Results: MSC derived from adipose tissue displayed the highest expression of collagen 1A2, collagen 3A1 and
decorin compared to MSC from all other sources and native tendon tissue (p < 0.01). Tenascin-C and scleraxis
expressions were highest in MSC derived from cord blood compared to MSC derived from other sources, though
both tenascin-C and scleraxis were expressed at significantly lower levels in all MSC compared to native tendon
tissue (p < 0.01).
Conclusions: These findings demonstrate that the MSC source impacts the cell properties relevant to tendon
regeneration. Adipose derived MSC might be superior regarding their potential to positively influence tendon
matrix reorganization.
Keywords: MSC, Mesenchymal stromal cell, Tendon, Adipose tissue, Bone marrow, Umbilical cord, Collagen,
Decorin, Scleraxis, Tenascin-CBackground
Tendon disease is a common cause of acute pain and
long-term mobility loss in athletes and elderly patients
[1-4]. Due to the predominantly degenerative character
of the disease, in many cases, regeneration following
acute injury cannot be achieved by conventional therap-
ies [1-4]. Cell-based therapies, however, were shown to
have positive effects on tendon regeneration not only in* Correspondence: burk@rz.uni-leipzig.de
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model [5-8].
Multipotent mesenchymal stromal cells (MSC) are
currently the most frequently used cell type in tendon
therapy based on their functions as connective tissue cell
progenitors and potent immunomodulators [9,10]. How-
ever, cells that correspond to the general definition of
MSC can be found in many different locations in the
body, and several studies showed that important differ-
ences exist between MSC derived from different sources
[11-16]. Thus, it is to be expected that the MSC source
also has an impact on the success of the clinical use of
the cells. In order to be able to choose the optimal cell
source, more knowledge is required on cell characteristicsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Aiming at regenerative tendon therapies, it is important
to consider that tendons are composed of mainly extracel-
lular matrix with a strictly hierarchical organization of
collagen fibrils [4,17]. The re-organization of these fibrils
and other extracellular matrix components after injury is
crucial for regaining the mechanical load capacity of the
tendon and thus to prevent re-injury. MSC application
was shown to improve the extracellular matrix structure
of damaged tendons and increased the collagen 1 content
towards normal levels [6,7], leading to the assumption that
replacement and remodelling of the extracellular matrix is
a major contribution of MSC to tendon healing. Aiming
to apply MSC that best possibly support the extracellular
matrix remodelling, it appears of great importance to
know the extent of the expression of tendon extracellular
matrix components in MSC from different tissue sources.
Therefore, in this study, it was aimed to further extend
and support our previous data on the comparative
characterization of equine MSC from different sources
[13,18]. For this purpose, MSC derived from different
tissue origins were used for a comparative assessment of
their gene expression levels of molecules that are relevant
to tenogenesis and to the composition and structure of
tendon extracellular matrix. Cells were isolated from
equine bone marrow (BM), adipose tissue (AT), tendon
tissue (TT), umbilical cord blood (UCB) and umbilical
cord tissue (UCT). Cells from all samples were subjected
to MSC characterization assays and to real-time reverse-
transcription polymerase chain reaction (RT-PCR) ana-
lyses of collagen 1A2, collagen 3A1, decorin, tenascin-C
and scleraxis expression. Native tendon tissue controls




Plastic-adherent cells could be isolated from all samples.
The cells were capable of adipogenic, osteogenic and
chondrogenic differentiation as confirmed by Oil Red O,
von Kossa or Alcian blue staining, respectively. Flow
cytometry revealed that they expressed CD29 and CD44,
and lacked expression of CD34, CD45 and MHCII,
although there were some variations between the percent-
ages of positive cells between donors and MSC sources
(data published elsewhere [18]).
Collagen expression
AT-MSC displayed a distinctively high collagen 1A2
expression, which differed significantly from MSC derived
from all other sources or from naT (p < 0.01). BM- and
UCT-MSC collagen 1A2 expression was overall lowest.
Although at a lower level than collagen 1A2, AT-MSC alsoshowed the highest collagen 3A1 expression, which was
significant compared to all other sample types (p < 0.01)
except for UCB-MSC. Correspondingly, the ratio of colla-
gen 1A2 expression to collagen 3A1 expression was higher
in AT-MSC than in MSC derived from all other sources
or in naT (p < 0.01). BM-MSC displayed the lowest ratio
(p < 0.01 compared to AT-MSC, TT-MSC and naT)
(Figure 1 and Additional file 1: Figure S1, Table 1).
Decorin expression
Decorin expression was generally higher in all MSC than
in naT, with the highest expression levels in AT- and
TT-MSC (p < 0.01 compared to naT and BM-MSC). Of all
MSC sources, UCB-MSC displayed the lowest decorin
expression (p < 0.01 compared to AT-, TT- and UCT-
MSC), with one single UCB-MSC sample showing an out-
standingly low expression (Figure 1 and Additional file 1:
Figure S1, Table 1).
Tenascin-C and scleraxis expression
Tenascin-C and scleraxis expression levels were both
significantly higher in naT than in MSC, irrespective of
their source (p < 0.01). For tenascin-C expression, no sig-
nificant differences between MSC from different sources
were found. Moreover, tenascin-C was expressed at overall
lower levels than the other genes investigated. For scler-
axis, differences were also evident between MSC from
different sources, with the highest median expression in
UCB-MSC (p < 0.01 compared to BM- and UCT-MSC)
(Figure 1 and Additional file 1: Figure S1, Table 1).
Discussion
In this study, we showed that significant differences exist
between the gene expression of tendon extracellular
matrix components in MSC derived from different sources,
which is of potential relevance for MSC application in
tendon therapy.
Most remarkably, there was a clear pattern that AT-
MSC expressed the extracellular matrix proteins colla-
gen 1A2, collagen 3A1 and decorin at highest levels.
In contrast, collagen expression was low in BM- and
UCT-MSC. Furthermore, the ratio of collagen 1A2 to
collagen 3A1 was highest in AT-MSC and lowest in
BM- and UCT-MSC. Collagen 1A2 is the most abun-
dant protein in healthy tendon tissue, while collagen
3A1 is also present but higher quantities are only
found during tendon repair [4,17]. Decorin is the most
abundant proteoglycan in tendon tissue and plays an
important role in the regulation of the collagen fibril
structure and cell proliferation as well as in stimulat-
ing immune responses [19]. MSC which highly express
these important extracellular matrix proteins may there-
fore have the best potential to positively influence matrix
reorganization during tendon healing.
Table 1 Tendon marker expression levels in MSC and naT
Target gene expression ratios (median (interquartile range))
Collagen 1A2 Collagen 3A1 Collagen 1A2/
collagen 3A1
Decorin Tenascin-C Scleraxis
BM-MSC 0,0322 (0,0306) 0,4163 (0,3440) 0,1066 (0,0225) 0,8936 (0,2955) 0,0006 (0,0006) 0,0112 (0,0230)
AT-MSC 3,9673 (0,7435)*,a,c,d,e 1,6649 (0,2418)*,a,c,e 2,2667 (0,3658) *,a,c,d,e 2,4893 (1,4706)*,a,d 0,0021 (0,0033) 0,0874 (0,0896)
UCT-MSC 0,0418 (0,0364) 0,3971 (0,3039) 0,1753 (0,0630) 0,8952 (0,5497)*,d 0,0010 (0,0002) 0,0129 (0,0031)
UCB-MSC 0,1888 (1,0578) 1,1562 (0,5452) 0,1741 (0,6369) 0,2870 (0,0270) 0,0034 (0,0047) 0,1019 (0,0889) a,c
TT-MSC 0,2010 (0,3445) a 0,5891 (0,2539) 0,4111 (0,5535) a 2,2928 (1,1165)*,a,d 0,0001 (0,0001) 0,0686 (0,1441)




Gene expression of tendon markers normalized to ACTB and GAPDH. P < 0.01 compared to *) native tendon tissue control (naT); a) bone marrow (BM)-multipotent
mesenchymal stromal cells (MSC); b) adipose tissue (AT)-MSC; c) umbilical cord tissue (UCT)-MSC; d) umbilical cord blood (UCB)-MSC; e) tendon tissue (TT)-MSC.
Corresponding data are shown in the additional file (Additional file 1: Figure S1).
Figure 1 Tendon marker expression in MSC relative to naT. Gene expression of tendon markers in multipotent mesenchymal stromal cells
(MSC) from different sources plotted as fold change to the median expression in native tendon tissue; bars indicate the median values, whiskers
the 99% confidence interval; p < 0.01 compared to *) native tendon tissue control (naT); a) bone marrow (BM)-MSC; b) adipose tissue (AT)-MSC; c)
umbilical cord tissue (UCT)-MSC; d) umbilical cord blood (UCB)-MSC; e) tendon tissue (TT)-MSC.
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both genes being expressed at lower levels in MSC than
in naT, differences between MSC samples were not as
eminent as those between the expression levels of
collagens or decorin. Among the MSC derived from
different sources, UCB-MSC displayed the highest
median expression and AT-MSC the second highest
median expression of both tenascin-C and scleraxis.
The glycoprotein tenascin-C is known to be present in
healthy tendon and is involved in the regulation of
collagen fibrillogenesis, but is also associated with
tendon disease [20,21]. However, although frequently
being used as an additional tenogenic differentiation
marker [22,23], tenascin-C is expressed in a wide variety
of cell types and its upregulation is also associated with
non-musculoskeletal diseases such as asthma or cancer
[24]. The transcription factor scleraxis is considered to be
a more specific tenogenic differentiation marker, as it was
found to be essential to tenogenesis, although further sig-
nals are required to contribute to tendon development
[25-27]. Scleraxis was further shown to regulate collagen
1A2 synthesis in cardiac fibroblasts [28] and may therefore
also play an important role in the re-organization of the
extracellular tendon matrix after injury. However, in the
current study using unstimulated MSC, a correlation
between scleraxis expression and collagen 1A2 expression
was not evident.
For healthy, adult tendon tissue, high expression levels
of collagen 1A2 and scleraxis and low expression levels
of tenascin-C were previously found to be most specific,
while cultured tenocytes displayed a significantly lower
scleraxis expression [21]. This is in accordance with the
current study, in which scleraxis was expressed at
significantly lower levels in all MSC compared to naT,
while collagen 1A2 and collagen 3A1 expression by
monolayer-cultured MSC, except for AT-MSC, did not dif-
fer significantly from naT. This supports the hypothesis that
scleraxis is a useful marker to distinguish undifferentiated
fibroblast-like cells and fully differentiated tenocytes.
Our findings also correspond with a previously published
study in which rat BM- and TT-MSC were compared
regarding their properties relevant to tendon regeneration
[29]. In this study, TT-MSC displayed superior properties
and a higher expression of tendon markers compared to
BM-MSC [29]. While in the current study, tendon marker
expression in TT-MSC was also higher than in BM-MSC,
AT-MSC diplayed an even higher marker expression
than TT-MSC. Therefore, based on the hypothesis that
re-organization and replacement of the extracellular matrix
is a major contribution of MSC to tendon healing, AT may
be the most promising cell source for tendon therapy.
There are further aspects which could have an influ-
ence on therapeutic success in tendon therapy. Besides
practical issues such as the required cell numbers andthe optimal way of applying the cells, MSC properties such
as their viability and their immunomodulatory capacity are
of potential importance. Previous studies showed that
differences between equine MSC from different sources
also exist with regard to their viability and proliferation
potential, at which AT-MSC have already been shown to
be superior compared to MSC derived from other sources
[13,15]. In contrast, no major differences between equine
MSC from different sources could be detected with regard
to their influence on lymphocyte proliferation and cytokine
expression [30], indicating a similar immunomodulatory
potential.
Taking into consideration their ease of harvest, high
viability and good immunomodulatory potential as well
as their high expression of tendon extracellular matrix
components as demonstrated in the current study, AT-
MSC appear to display several advantages for clinical
use in tendon therapy.
However, the current study is of preliminary character.
Comparative studies of MSC from different sources using
in vitro models that mimic tenogenic conditions [31] may
help to further substantiate our hypothesis. Eventually, it re-
mains to be investigated whether a high expression of extra-
cellular matrix proteins in vitro finally leads to the intended
results in terms of replacement and re-organization of the
extracellular matrix after in vivo application.
Conclusions
The current study demonstrates that MSC from differ-
ent sources display different tendon marker expression
patterns, particularly with respect to the most important
tendon extracellular matrix components. As improvement
in matrix re-organization has been shown to be the major
beneficial effect of MSC in tendon therapy, this finding is
of potential clinical relevance. AT-MSC showed the high-
est expression of tendon extracellular matrix components
and may therefore be most potent to positively influence
extracellular matrix re-organization after tendon injury.
Methods
Sample collection
For primary cell isolation, UCB and UCT were recovered
from healthy foals and BM, AT and TT were recovered
from healthy adult horses (age range: 3–18 years), as de-
scribed previously [13] and with approval by the local ethics
committee (Landesdirektion Leipzig, Germany, A13/10).
Further tendon samples were collected from the superficial
digital flexor tendons of animals which had been eutha-
nized for unrelated reasons and immediately stored
at -80°C to be used as the naT reference for RNA analysis.
Cell culture and characterization
Cells were isolated by density gradient centrifugation
from BM and UCB and by collagenase I digestion from
Table 2 Primer sequences
Equine gene Forward primer Reverse primer Accession number PCR product in bp
ACTB ATCCACGAAACTACCTTCAAC CGCAATGATCTTGATCTTCATC NM_001081838.1 174
GAPDH TGGAGAAAGCTGCCAAATACG GGCCTTTCTCCTTCTCTTGC NM_001163856.1 309
Collagen 1A2 CAACCGGAGATAGAGGACCA CAGGTCCTTGGAAACCTTGA XM_001492939.1 243
Collagen 3A1 AGGGGACCTGGTTACTGCTT TCTCTGGGTTGGGACAGTCT XM_001917620.2 216
Decorin ACCCACTGAAGAGCTCAGGA GCCATTGTCAACAGCAGAGA NM_001081925.2 239
Tenascin-C TCACATCCAGGTGCTTATTCC CTAGAGTGTCTCACTATCAGG XM_001916622.2 163
SleraxisnaT TACCTGGGTTTTCTTCTGGTCACT TATCAAAGACACAAGATGCCAGC NM_001105150.1 51
ScleraxisMSC AGAGAAAGTTGAGCAAGGACC TCAAAGACACAAGATGCCAGC NM_001105150.1 294
Primer sequences used for real-time reverse transcription polymerase chain reaction.
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then seeded into culture flasks in low glucose (1 g/L)
Dulbecco’s modified eagle medium (Life Technologies
GmbH) supplemented with 20% fetal bovine serum (Sigma
Aldrich, Taufkirchen, Germany), 1% penicillin-streptomycin
(PAA Laboratories GmbH, Coelbe, Germany) and 0.1%
gentamycin (Life Technologies GmbH), and incubated at
37°C, 95% humidity and 5% CO2 for selection of plastic-
adherent cells and their further expansion. Passage 3 cells
were used to confirm their trilineage differentiation poten-
tial into adipocytes, osteoblasts and chondrocytes [13], as
well as for the assessment of surface marker expression by
flow cytometry [18].
RNA analysis
Five samples of UCB-MSC and 6 samples of each BM-,
AT-, TT- and UCT-MSC (passage 3) as well as naT were
subjected to RNA analysis by real-time RT-PCR.
Total RNA of MSC was isolated using the RNeasy®
Mini Kit (Qiagen, Hamburg, Germany) according to
instructions of manufacturers (protocol version 09/2010).
Frozen naT samples were sliced in 12 μm sections with a
microtome CM 3050 S equipped with cryochamber (Leica
Microsystems, Wetzlar, Germany) and incubated for
60 min at 55°C in homogenization buffer (15 mM HEPES,
2.5 mM KCl, 68.5 mM NaCl, 450 μM Na2HPO4, 17.5 mM
EDTA, 27.5 mM glucose at pH 7) containing 100 μg/ml
proteinase K (Ambion® Life Technologies, Darmstadt,
Germany). To homogenize the sample, lyzed tendon tissue
was passed through a 20-gauge needle several times. Total
RNA of tendon tissue homogenate was purified with phe-
nol/chloroform extraction and isopropanol precipitation.
DNase-treated RNA was reverse transcribed using the
RevertAid H Minus First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific, Dreieich, Germany) or the
Omniscript RT Kit (Qiagen) with oligo-dT18 primers as
described by the manufacturers. Relative quantification of
cDNA was performed with a 7500 Real Time PCR System
(Applied Biosystems, Foster City, USA) and SYBR® Green
as double-strand DNA-specific dye (iQ™SYBR® Green
Supermix, Bio-Rad Laboratories, Hercules, USA). Primersamplifying the respective genes are listed in Table 2 and
corresponding Ct values were used to analyze gene ex-
pression. RT-PCR analysis of scleraxis expression was per-
formed with two different primer sets for native tendon
tissue and isolated MSC. To confirm that relative quantifi-
cation of both sample types was comparable, expression
of scleraxis in MSC derived from BM, AT, UCT, UCB and
TT was analyzed using both primer sets. Obtained data
showed that relative expression of scleraxis was similar in
MSC derived from different sources irrespective of the
primer set used (data not shown). Therefore, scleraxis
mRNA expression levels of all samples can be compared.
Primer efficiency (Egene) was calculated after serial di-
lution of template cDNA and target gene expression
levels were normalized to the reference genes ACTB and








Further, fold changes (FC) of MSC gene expression
compared to naT gene expression were calculated from
the normalized gene expression ratios:
FCincrease ¼ ratioMSC sample=median rationaT
 
‐1




Kruskall-Wallis one way analyses of variance and subse-
quent Mann–Whitney-U tests were performed to analyze
differences between the normalized gene expression levels
of the sample groups. P < 0.01 was considered as significant.
Additional file
Additional file 1: Figure S1. Tendon marker expression levels in MSC
and naT. Gene expression of tendon markers in multipotent mesenchymal
stromal cells (MSC) from different sources and in native tendon tissue (naT),
given as ratios normalized to ACTB and GAPDH. BM: bone marrow; AT:
adipose tissue; UCB: umbilical cord blood; UCT: umbilical cord tissue;
TT: tendon tissue.
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